A phase 3 study among Chinese patients for an eye drug co-developed by Shanghai Henlius Biotech (HKG:2696) and Essex Bio-Technology (HKG:1061) reached the primary study endpoints, according to separate Wednesday filings with the Hong Kong bourse.
The two companies co-developed the HLX04-O injection for wet age-related macular degeneration patients.
The drug contains thee recombinant anti-vascular endothelial growth factor humanised monoclonal antibody, according to Essex's filing.
Wet age-related macular degeneration patients experience abnormal growth of blood vessels under the retina which could lead to rapid vision loss.
Shares in Essex surged nearly 11%, while that of Henlius fell 4% during late morning trading Thursday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。